Lupin gets ISO 14001 and ISO 45001 certification across all its Indian manufacturing sites, RnD Center, Corporate Office

Published On 2024-05-16 06:45 GMT   |   Update On 2024-05-16 06:45 GMT

Mumbai: Global pharma major Lupin Limited has announced that all 12 of its manufacturing sites, its R&D Center and corporate office in India have successfully completed rigorous audits and been certified by DNV for ISO 14001 — Environment Management Systems (EMS), and ISO 45001 — Occupational Health and Safety Management System (OHSMS).

ISO 14001 is an internationally recognized standard for Environmental Management Systems.

"This certification demonstrates Lupin’s dedication to minimizing its environmental footprint and fostering sustainable practices across its operations. The ISO 45001 certification underscores Lupin’s unwavering commitment to ensuring the health, safety and well-being of its employees and stakeholders," the release stated.

Commenting on this remarkable achievement, Nilesh Gupta, Managing Director, Lupin, said, “We are very proud of this achievement; it acknowledges our steadfast commitment to excellence in environmental stewardship and workplace safety and is a reflection of our ongoing efforts to integrate sustainable practices into our business operations and prioritize the health and safety of our people.”

Advertisement

Read also: Lupin ropes in Jeffrey Kindler, Alfonso Zulueta as Independent Directors

Lupin is an innovation-led transnational pharmaceutical company headquartered in Mumbai, India. The Company develops and commercializes a wide range of branded and generic formulations, biotechnology products, and APIs in over 100 markets in the U.S., India, South Africa, and across the Asia Pacific (APAC), Latin America (LATAM), Europe, and Middle East regions. The Company specializes in the cardiovascular, anti-diabetic, and respiratory segments and has a significant presence in the anti-infective, gastro-intestinal (GI), central nervous system (CNS), and women’s health areas.

Lupin is the third-largest pharmaceutical company in the U.S. by prescriptions. The company invested 7.8% of its revenue in research and development in FY24. Lupin has 15 manufacturing sites, 7 research centers.

Read also: Lupin ropes in Jeffrey Kindler, Alfonso Zulueta as Independent Directors

Tags:    

Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement/treatment or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2024 Minerva Medical Treatment Pvt Ltd

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News